imILT®protocol was developed to kill solid cancer tumors while potentially stimulating an immunological defense against any remaining tumor cells, even those that are outside, or distant from, the treated area.
An optical laser fiber is inserted into the tumor. Laser light is then used to heat the tumor, in a controlled way, intending to cause a process where the tumor then dies within a few days and antigens may leak out of the tumor cells. As shown in preclinical studies the antigens activate the body's immune system, which then also attacks other tumors and metastases.
This immunological effect is generated by treating the tumor with a temperature that is so low that the tumor's antigenic proteins are preserved. These proteins come into contact with the immune system and may stimulate an immunological defense against tumor disease.
An evaluation of CLS’ products for treatment with Focal Laser Ablation (FLA) was initiated in the beginning of 2017.
CLS’ products are in clinical use for treatment with FLA/LITT and evaluated in an ongoing clinical study regarding treatment of early stage prostate cancer at Toronto University Hospital.
Image-guided FLA is a method primarily used today for treatment of early localized prostate cancer (PCA). While imILT® is aimed at activating the immune system, FLA is intended to kill the target tumor, which is done by using a higher temperature and shorter treatment time compared to imILT®. The treatment is performed by a urologist or an interventional radiologist using MRI or CT images and ultrasound.